Translational Therapeutics Core

The Translational Therapeutics Core (TTC) focuses on accelerating preclinical development of new therapeutics for Alzheimer’s disease (AD) and AD-related dementia (ADRD) through human target validation. This includes supplying clinically-characterized human brain tissue (both frozen and fixed), as well as blood and cerebrospinal fluid, from patients and matched controls. The goal is to accelerate translation of research in AD/ADRD, and also to incorporate scientists currently outside of the field of AD/ADRD whose findings could advance AD/ADRD treatment in novel ways.

The TTC is located at University Hospitals (UH) of Cleveland Medical Center, and is directed by Andrew A. Pieper, MD PhD, who also serves as Director of the Neurotherapeutics Center of the Harrington Discovery Institute of UH. The connection to the Harrington Discovery Institute also offers opportunity for guidance and support in drug development for AD/ADRD for TTC-supported investigators.

Applications for TTC tissue are welcomed from researchers working on projects related to putative therapeutic processes for AD / ADRD. Applications are rigorously evaluated by the team below, and successful applications are guided through pilot proof of principle studies, followed by definitive and highly-powered studies. Modest funds are available to support the translational studies in the scientist’s home lab, if requested.

The TTC works closely with the Neuropathology Core (NPC) and the Research Education Component of the CARDC. Starting in 2021, the TTC will also identify and financially support an annual TTC-REC fellow.

Researchers may request tissue through contacting


Andrew A. Pieper, MD PhD, Translational Therapeutics Core Leader

Coral J. Cintrón-Pérez, M.B.A.,  TTC coordinator

James Leverenz, MD, Co-Investigator

Jeffrey L. Cummings, MD, Co-Investigator

Babak Tousi, MD, Co-Investigator

Alan J. Lerner, MD, Co-Investigator